Cabaletta Bio

Contributing Author

Recent Articles by Cabaletta Bio

May-14	Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update CABA GlobeNewswire
May-14	Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting CABA GlobeNewswire
May-04	Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering CABA +30.27% GlobeNewswire
Apr-28	Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel CABA GlobeNewswire
Apr-27	Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting CABA GlobeNewswire
Mar-23	Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update CABA GlobeNewswire
Feb-24	Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference CABA +13.45% GlobeNewswire
Feb-05	Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 CABA -7.17% GlobeNewswire
Jan-12	Cabaletta Bio Announces 2026 Strategic Priorities CABA +5.24% GlobeNewswire
Nov-10	Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update CABA GlobeNewswire
Nov-04	Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December CABA -10.30% GlobeNewswire
Oct-27	Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 CABA +12.96% GlobeNewswire
Oct-14	Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant CABA +16.06% GlobeNewswire
Oct-09	Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress CABA -18.60% CABA +18.26% GlobeNewswire
Aug-27	Cabaletta Bio to Participate in Upcoming Investor Conferences in September CABA GlobeNewswire
Aug-07	Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update CABA GlobeNewswire
Jun-11	Cabaletta Bio Announces Pricing of Public Offering of Securities CABA -25.53% GlobeNewswire
Jun-11	Cabaletta Bio Announces Proposed Public Offering of Securities CABA -25.53% GlobeNewswire
Jun-11	Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress CABA -25.53% GlobeNewswire
May-29	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference CABA GlobeNewswire
May-15	Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts CABA +39.23% GlobeNewswire

Cabaletta Bio

Recent Articles by Cabaletta Bio

Upgrade your Finviz experience